Title_Novartis_Logo

May 8th 2018

**To:** The Editor-In-Chief of *the Journal of Visualized Experiments*

**Re:** Submission of an article entitled:

**“Myeloid Innate Signaling Pathway Regulation by the CARD/BCL10/MALT1 Complex”**

As responsible of the research project and on behalf of my coauthors, I would like to submit today our manuscript for consideration. There are no competing financial interests in relation to the work described. None of the submitted material is under consideration elsewhere.

MALT1, a key component of antigen receptor signaling cascades in lymphocytes, has attracted a lot of attention since the discovery of its proteolytic activity in 2008. Current understanding indicates that MALT1 activation occurs during assembly of a canonical “CBM complex”, which relays activation downstream of receptor activation. However, how MALT1 regulates innate signaling pathways is not well understood.

The purpose of this article is to study both human and mouse myeloid systems with selective tool compounds to address which innate pathways depend on MALT1. Several cell types were prepared and analyzed, thus providing guidance for those interested in setting up similar pharmacological approaches using primary cells.

We hope this article can be useful to the research community.

Thank you for your attention.

Best regards,

Frederic Bornancin

Corresponding Author

Frédéric Bornancin, PhD

Senior Research Investigator

Novartis Institutes for BioMedical Research, Forum 1, CH-4056 Basle, Switzerland

Phone: +41 79 444 46 37

Email: [frederic.bornancin@novartis.com](mailto:frederic.bornancin@novartis.com_)